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Reliably estimating prevalences of atopic children: an
epidemiological study in an extensive and representative
primary care database
David H. J. Pols1, Mark. M. J. Nielen2, Joke C. Korevaar2, Patrick J. E. Bindels1 and Arthur M. Bohnen1
Electronic health records stored in primary care databases might be a valuable source to study the epidemiology of atopic disorders
and their impact on health-care systems and costs. However, the prevalence of atopic disorders in such databases varies
considerably and needs to be addressed. For this study, all children aged 0–18 years listed in a representative primary care database
in the period 2002–2014, with sufﬁcient data quality, were selected. The effects of four different strategies on the prevalences of
atopic disorders were examined: (1) the ﬁrst strategy examined the diagnosis as recorded in the electronic health records, whereas
the (2) second used additional requirements (i.e., the patient had at least two relevant consultations and at least two relevant
prescriptions). Strategies (3) and (4) assumed the atopic disorders to be chronic based on strategy 1 and 2, respectively. When
interested in cases with a higher probability of a clinically relevant disorder, strategy 2 yields a realistic estimation of the prevalence
of atopic disorders derived from primary care data. Using this strategy, of the 478,076 included children, 28,946 (6.1%) had eczema,
29,182 (6.1%) had asthma, and 28,064 (5.9%) had allergic rhinitis; only 1251 (0.3%) children had all three atopic disorders.
Prevalence rates are highly dependent on the clinical atopic deﬁnitions used. The strategy using cases with a higher probability of
clinically relevant cases, yields realistic prevalences to establish the impact of atopic disorders on health-care systems. However,
studies are needed to solve the problem of identifying atopic disorders that are missed or misclassiﬁed.
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INTRODUCTION
The rising prevalence of atopic disorders in children are an
important global health problem.1, 2 Atopy is a (genetic)
predisposition toward developing allergic hypersensitivity. The
clinical manifestation of atopy is allergy. However, not all allergies
are atopic. In this study, the word ‘‘atopic’’ refers to this genetically
mediated predisposition, resulting in the clinical diagnosis by a
general practitioners (GPs) of eczema, asthma, and allergic rhinitis.
In many countries, primary care professionals, e.g., family doctors/
GPs, diagnose and treat these atopic children. In the Netherlands,
GPs, are in the frontline of the health-care system, are freely
accessible, and use uniform coding systems for recording
diagnosis and prescriptions. In principle, all non-institutionalized
residents in the Netherlands are registered in a general practice,
even if they do not visit the GP. Therefore, the electronic health
records (EHR) stored in primary care databases contain valid
information about the epidemiological denominator, making it a
potentially important source of epidemiological data.
A meta-analysis based on questionnaires in the ‘‘open popula-
tion’’, including children of all ages (0–18 years), showed average
one-year worldwide prevalences for eczema, asthma, and
rhinoconjunctivitis of 7.9%, 12.0%, and 12.7%, respectively.3
However, the accuracy of data obtained from a questionnaire
depends on various items, including the accuracy and knowledge
of the responders, and the deﬁnitions used by the researcher.4
When comparing ‘‘open population’’ data with data obtained from
the EHRs of general practices, lower annual prevalences for
eczema, asthma, and rhinoconjunctivitis were found, ranging (on
average) from 1.8–9.5%, 3.0–6.5%, and 0.4–4.1%, respectively.5
Since these diagnoses are based on the assessment of a physician,
these data could potentially form a more speciﬁc epidemiological
source. Unfortunately, the annual prevalences of atopic disorders
in general practice databases vary considerably;5 moreover, since
these differences cannot be fully explained by country or year of
study, this variation needs further consideration. Part of this
variation might be explained by the fact that GPs often work
with a ‘‘probability diagnosis’’ that inevitably creates a risk of
misclassiﬁcation, which could result in either over- or under-
estimation. Other possible explanations could be a variation in
clinical knowledge and skills of the GP. Furthermore, there might
also be some coding difﬁculties, when coding diseases in EHRs.
Some studies using primary care data have presented life-time
cumulative prevalences;6–9 the prevalences found for eczema,
asthma, and rhinoconjunctivitis ranged (on average) from
7.2–36.5%, 4.2–22.9%, and from 1.0–11.4%, respectively. However,
the question arises as to what extent these life-time cumulative
prevalences provide relevant information compared with annual
point prevalences, knowing that these disorders are not always
chronic.
To establish the impact of atopic disorders on health-care
systems and their related costs, a more accurate estimation is
required of the prevalence of atopic disorders derived from
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general practice databases. This study investigates the risk of
misclassiﬁcation, which could either result in overestimation or
underestimation of atopic disorders. The results for annual point
prevalence vs. life-time cumulative prevalence were compared
using four different strategies using an extensive and representa-
tive primary care database.
RESULTS
Patient selection
A total of 660,512 eligible children (aged 0–18years) were derived
from the The Netherlands Institute for Health Services Research-
Primary Care Database (NIVEL-PCD (period 2002–2014)). Of these,
24,477 (3.7%) children did not pass the data quality checks
(Appendix 1) and 157,959 (23.9%) children were excluded because
they had less than 3 years of follow-up. The ﬁnal study group
included 478,076 children, of whom 51.1% were male. Mean age
of the children when entering the NIVEL-PCD was 7.2 (SD 6.0)
years: mean follow-up time was 6.6 (SD 4.7) years.
Prevalence of atopic eczema
According to strategy 1 and 2, the point prevalence rises to a
maximum at age 2 years of 9.0% and 6.9%, respectively. At age 18
years this prevalence drops to 3.0% and 2.5%, respectively.
However, if the disorder is considered to be chronic for research
purposes, based on strategy 3 and 4 the lifetime cumulative
incidences at age 18 years ranges from 24.0–43.8% (Fig. 1).
Prevalence of asthma
The point prevalence of asthma shows a steep rise in the ﬁrst two
years of life with a maximum prevalence at age 7 years according
to strategy 1 (5.5%) and strategy 2 (4.9%), and drops slightly at age
18 years to 4.3% and 3.6%, respectively. The (for research
purposes) calculated lifetime cumulative incidences at age 18
year is 19.3–26.8% (Fig. 2).
Prevalence of allergic rhinitis
In contrast to eczema and asthma, allergic rhinitis shows a
relatively consistent rise in prevalence over the years. For
strategy1 and 2 the maximum prevalence at age 18 years is
6.2% and 5.7%, respectively. Assuming allergic rhinitis to be a
chronic disorder for research purposes, the lifetime cumulative
incidence also reaches its maximum at age 18 years, but is
substantially higher, i.e., 16.0–22.5% (Fig. 3).
Prevalence of atopic triad
The atopic triad is estimated for research purposes. Depending on
the strategy used, the maximum prevalence for strategy 1 (0.8%) is
reached at age 6 years and that for strategy 2 (0.4%) at 7 years.
Both scenarios show a decrease resulting in a point prevalence at
age 18 years of 0.5% and 0.3%, respectively. For all four strategies,
a maximum prevalence of 1.4% is observed (Fig. 4).
Interrelationship between the atopic disorders
Interrelationships between atopic disorders are well known. Of the
478,076 children, based on strategy 228,946 children (6.1%) had
Fig. 1 Prevalence by age for atopic eczema
Fig. 2 Prevalence by age for atopic asthma
Fig. 3 Prevalence by age for allergic rhinitis
Fig. 4 Prevalence by age for atopic triad
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eczema, 29,182 (6.1%) had asthma, and 28,064 (5.9%) had allergic
rhinitis. Only 1251 (0.26%) children had all three atopic disorders.
This is a 12-fold higher prevalence than could be expected by
chance (0.022%) based on the three prevalences of the individual
atopic disorders. In total 21,862 children had eczema only, 20,382
children had asthma only, and 19,835 children had allergic rhinitis
only and no other atopic comorbidity. Of all children with asthma,
19.2% also had allergic rhinitis (Fig. 5).
DISCUSSION
Main ﬁndings
To retrieve more relevant data from primary care databases, four
different strategies were explored. Based on the results of this
study, strategy 2, which at least selects cases with potentially more
clinically relevant disorders and does not assume that a child will
have the disorder for life, seems preferable when interested in the
current burden of atopic disorders. Of the 478,076 children ﬁnally
included, after applying strategy 2, 6.1% had eczema, 6.1% had
asthma and 5.9% had allergic rhinitis; these annual point
prevalences are in accordance with those found in a recent
systematic review.5 Only 0.26% children had all three atopic
disorders; this is a 12-fold higher prevalence than could be
expected by chance based on the three individual prevalences of
the atopic disorders (0.022%). This phenomenon was recently
described in a meta-analysis3 and supports the hypothesis that
there could be a fourth distinct group of atopic children that have
all three disorders, i.e., they may have their own unique
characteristics.
Interpretation of ﬁndings in relation to previously published work
Showing the data simply as recorded in the GP’s database
(strategy 1) will result in a risk of overestimation. A possible
solution was offered in the literature by applying two selection
criteria, i.e., at least two relevant consultations and at least two
relevant prescriptions. When applying these criteria, the annual
point prevalences only dropped slightly (as expected), but
potentially show more clinically relevant cases. The results now
more closely approach the annual point prevalences reported in
the literature.5 However, ideally a gold standard is needed to
identify atopic children. Such a gold standard could probably be
the evidence of sensitization by speciﬁc IgE.10 Checking speciﬁc
IgE is now a requirement of assessment of the patient with
asthma. When studying the observed differences between annual
point prevalence and cumulative life-time prevalence, a greater
understanding of the natural course of these atopic disorders is
required. In Germany, Illi et al.11 studied the natural course of
atopic dermatitis in a cohort of 1314 children from the general
population, until age 7 years. The prevalence increased to 21.5% at
2 years of age, but 43.2% were in complete remission by age 3
years. Regarding asthma, Jenkins et al.12 screened 7-year-olds for
this condition. The study was repeated 25 years later in a random
sample (n = 750); a quarter of those who had asthma as a child,
reported asthma in adulthood. According to Sears, about half to
two-thirds of the children with asthma recover.13 An explanation
for this observed recovery could be that viral infections are the
main cause of wheeze before the age of six rather than allergic
asthma. This is supported by data from a different Dutch primary
care study, which showed that for those children diagnosed with
asthma between the age of 0–4 years, ≥ 60% were no longer
known as such by the GP after 2 years, and after 10 years 80% no
longer carried this diagnosis.14 When the same children were
screened for asthma at a later age (10–23 years), 45% still had
asthma.15 Finally, regarding allergic rhinitis, a prospective study on
the course of hay fever in 738 individuals (with an average follow-
up of 23 years) showed that in a majority of the adult patients the
symptoms of hay fever reduce over the years.16 Another
prospective study (n = 257, mean follow-up to 8 years) on various
forms of allergic rhinitis (conﬁrmed by the presence of speciﬁc IgE
to pollen, pets, or dust mites), looked at the percentage of patients
with complete remission of symptoms.17 This study found
complete remission of symptoms in 12% of patients with pollen
allergy, in 19% of patients with an allergy to pets, and in 38% of
patients with house dust allergy. The third and fourth strategy
assumed that a child would have the atopic disorder for life,
resulting in cumulative life-time prevalences that are substantially
higher than those reported in the literature.5 Based on all the
available evidence, it seems incorrect to conclude that atopic
disorders are by deﬁnition chronic and, therefore, we consider
strategies 3 and 4 to be less reliable and are not recommended.
Even though the underlying assumptions made for strategies 3
and 4 are not realistic, the differences found between strategy 2
and 4 nevertheless provide an estimation of the number of
children that show complete reduction of symptoms. This results
in remission rates of 84%, 68%, and 43% at age 10 years and 90%,
81%, and 64% at age 18 years for eczema, asthma, and allergic
rhinitis, respectively.
Strengths and limitations of this study
For the present investigation, we used an extensive and
representative primary care database; the number of included
cases gives this study substantial power. The potential for using
primary care databases of routinely collected clinical data for
epidemiology and health policy is, therefore, enormous. However,
to use this potential, sound methodologies are needed to turn the
huge amount of raw data into meaningful information. An easy to
apply strategy is presented in this study to select potentially more
clinical relevant cases.
Unfortunately, there is an important limitation. The present
study is based on the assumption that the relevant International
Classiﬁcation of Primary Care (ICPC) codes are not missed. For
example, a child that has ICPC code R03 (wheezing) and regularly
uses inhalation corticosteroids probably has asthma. However,
when the child is not coded correctly as having R96 (asthma), or is
not coded at all, it will not be possible to identify this child as
having asthma. To include this child as an asthmatic patient, a
new or adjusted episode R96 needs to be created by the
researcher. Although this is a complex problem, there are different
ways to deal with it. The most sensitive methodis to study the
complete EMR of the individual patient; unfortunately, this is very
time consuming and raises privacy issues. Another option is to use
computer software that analyses free text; however, the accuracy
Fig. 5 Venn diagram of the overall prevalence (total population:
478,076 children)
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of this method is determined by the quality of the script used.
A faster and probably more consistent way of identifying a child, is
to use ‘‘templates’’ that are based on a combination of routinely
and standardized coded data from EHRs such as standardized
measurements, ICPC-coded comorbidity, and Anatomical Ther-
apeutic Chemical (ATC)-coded prescriptions. According to a recent
study,18 based on general practice data, children diagnosed with
asthma can be reliably identiﬁed with a range of medication
proxies (sensitivity 54% and positive predictive value 84%).
However, the use of prescription data for the identiﬁcation of
children diagnosed with eczema and allergic rhinitis is more
problematic; one reason for this is that (some) reliever medication
is freely available over the counter. Comorbidity data could also be
used as a source to identify misclassiﬁed children. However,
although many studies have shown a relationship between
different comorbidities and atopic disorders, to our knowledge
no study has used comorbidity to identify atopic disorders.
Food allergies are also closely associated with atopic disorders.
Unfortunately, in this study it was not possible to reliably analyze
food allergies, since the ICPC-1 coding system does not have
speciﬁc codes for food allergies.
Implications for future research, policy, and practice
The results of this study emphasize the importance of better
coding. Further research is needed to create proxies based on
standardized coded variables to identify atopic disorders in order
to address the risk of underestimation. Some attempts have been
made, such as Asthma Critic (a decision-support system for
asthma and chronic obstructive pulmonary disease),19 which aims
to generate patient-speciﬁc feedback based on routinely recorded
data in EMRs. In order to address the risk of overestimation, future
clinical guidelines should also include criteria that help physicians
to identify atopic diagnoses, which are no longer clinically
relevant.
In the future, research using extensive databases will become
more popular due to their increased availability. Epidemiological
studies on atopic disorders are reaching the limit of what can be
achieved through conventional hypothesis-driven research.20 This
new era of ‘‘big data’’ allows smarter and more powerful statistical
analysis, especially when analyzing metadata. Future collaborative
analysis could also facilitate interdisciplinary dialogue between
clinicians and scientists.
CONCLUSIONS
In conclusion, research using extensive databases will become
more popular due to their increased availability; we are now in the
era of ‘‘big data’’. Future collaborative (meta) analysis on the valid
use of routinely recorded clinical data from big databases is
needed in order to be able to develop valid search strategies to
identify atopic children. This study contributes to a better
understanding of the use of primary care data. Based on the
results of this study, strategy 2, which at least corrects for the risk
of overestimation due to misclassiﬁcation and does not assume
that a child will have the disorder for life, seems preferable and
can easily be applied. The limitations of primary care data that
result in underestimation are more challenging, since some
patients are also able to self-manage their disorder. Studies are
required to create proxies based on routinely recorded and
standardized clinical coded data that can help identify atopic
disorders that are missed or misclassiﬁed.
METHODS
Study population
NIVEL-PCD is based on routinely recorded data in EHRs of all listed patients
in the participating practices. In 2014, about 500 general practices
participated, including data of about 1,700,000 patients (www.nivel.nl/
en/dossier/nivel-primary-care-database). EHR data include a variety of
information regarding type of consultation, morbidity, and prescriptions.
Data were available from 2002–2014 and are representative for the Dutch
population.21 Primary care physicians recorded morbidity using the ICPC-1.
The ICPC is a classiﬁcation method for primary care encounters and is
accepted by the WHO.22 Dutch GPs cluster relevant consultations,
prescriptions, and referrals in ICPC classiﬁed episodes of care.
For the present study, we only used morbidity data from the EHRs of
general practices with sufﬁcient data quality, fulﬁlling the following criteria:
at least 500 listed patients (standard practice: 2350 patients), complete
morbidity registration (deﬁned as ≥ 46 weeks/year), and sufﬁcient ICPC
coding of diagnostic information (deﬁned as ≥ 70% of the recorded
disease episodes labeled with an ICPC code).
Selection of atopic children
From the general practices in NIVEL-PCD, all listed children (aged 0–18
years) with sufﬁcient data (in the period 2002–2014) were selected. For
each child, a minimum follow-up of 3 years was required to reduce the risk
of registration bias. According to NIVEL, Dutch GPs see about 77% of their
patients at least once a year;23 therefore, a 3-year follow-up allows the GP
sufﬁcient time to diagnose a child with atopic disorders. Follow-up ends
when a child would change to a GP that is not working in a NIVEL-PCD
clinic, or when the child would have died. For these children, the following
descriptive data were routinely collected: period in which the individual
child was registered in the clinic, unique code of the GP practice, sex, and
year and quarter of birth. For all these children, ICPC-coded episodes
regarding atopic eczema (S87), asthma (R96), and allergic rhinitis (R97)
were extracted when applicable with their starting and closing dates.
Episode (re)construction
At each new encounter in general practice, a Dutch GP starts a new
episode of care. If the patient returns to the GP for the same disorder, or
when the patient orders (repeat) medication relevant to that disorder, it
should be recorded as a follow-up contact within that speciﬁc episode of
care.
In the present study, four different strategies were examined with the
aim to obtain a better understanding of prevalence estimates based on
primary care data: two strategies are related to the beginning of an
episode of care and the other two are related to the ending of an episode
of care. Table 1 presents a summary of the strategies.
Concerning the start of an episode, either the episodes of care were
used as recorded in the database and one accepts the risk of
overestimation due to working with ‘‘probability diagnoses’’, or these
episodes of care were corrected by applying selection criteria, focusing on
cases with higher probability of a clinical relevant disorder (see below).
With respect to the ending of an episode of care, two identical strategies
Table 1. Summary of the four strategies examined
Strategy 1 Presents the prevalence based on the recorded episodes of care
Strategy 2 Presents the prevalence based on corrected episodes of care (by applying selection criteria: at least two relevant consultations
and at least two relevant prescriptions)
Strategy 3 Presents the prevalence based on the recorded episodes of care, but the disorders are considered to be chronic
Strategy 4 Presents the prevalence based on corrected episodes of care (by applying selection criteria from strategy 2), but the disorders are
considered to be chronic
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were applied. Either the episodes of care were used as recorded or these
episodes of care were corrected by extending the closing date, assuming
that atopic disorders were chronic.
Start of an episode of care. Strategy 1 uses the episode of care as
recorded in the EHRs of the GP and accepts a risk of overestimation. In the
second strategy (strategy 2), correcting for a possible overestimation,
different selection criteria were taken into consideration based on our
previous review.5 Using these criteria, ICPC codes and their related
episodes of care can be corrected, reducing the risk of misclassiﬁcation and
selecting cases with a higher probability of a clinical relevant disorder. For
example, if a GP suspects that a child has asthma and labels the encounter
accordingly with R96, this can later be corrected as not having asthma if
this child never visits the GP again for this problem or never receives the
appropriate medication. In practice, this implies the following require-
ments: at least two episode-related contacts (either consultations, home
visits, telephone calls, or prescriptions) and a minimum of two relevant
prescriptions had to be prescribed. The ATC Classiﬁcation System was used
to identify relevant prescriptions. For eczema the ATC code D07
(dermatological corticosteroids) was used, for asthma the ATC code R03
(drugs for obstructive airway diseases) was used, and for allergic rhinitis
the ATC codes R01AC (nasal preparation of antiallergic agents, excl.
corticosteroids), R01AD (nasal preparation of corticosteroids) and R06
(antihistamines for systemic use) were used. These medication proxies
have been tested by Mulder et al.18 Since some EHRs do not routinely link
relevant prescriptions in the correct episodes, all recorded prescriptions in
the EHRs were studied. When a patient could not meet the criteria of
having at least two contacts and two relevant prescriptions, the patient is
considered to be a child in the ‘‘population at risk’’.
Closure of an episode of care. In the present study, two strategies (3 and 4)
considered the atopic disorders to be chronic for research purposes. Since
data is available for all patients in our database regarding the ﬁrst date on
which a diagnosis was made (each child could be incident only once in its
life), it is possible to determine the number of children diagnosed at each
year and for each age. When adding these annual numbers for the
consecutive years of interest, one in fact calculates a cumulative incidence.
Since no data is missing regarding the ﬁrst date of the disorder, this
cumulative incidence will approximate a cumulative life-time prevalence.
Strategy 3 shows the cumulative incidences based on strategy 1, and in
strategy 4 it is based on strategy 2.
Atopic triad. Finally, ‘‘atopic triad’’ episodes were created for research
purposes, based on a suggestion reported in a meta-analysis.3 Such an
episode was only created when a child was diagnosed with all three atopic
disorders. The ﬁrst date when a child was diagnosed with at least one of
the disorder, is considered the starting date of the ‘‘atopic triad’’ episode.
The closing date of the episode is equal to the last contact date recorded
for one of the atopic disorders.
Statistical analyses
Annual point prevalence rates were calculated as percentages on the ﬁrst
of January for each age (0–18 years). The denominators for the calculations
were also determined on this date. Cumulative life-time prevalences, based
on the assumption that the disorder is chronic, are based on the
cumulative incidences (strategy 3 and 4). This cumulative incidence equals
a life time prevalence, since the complete medical history of a patient is
available in the EHRs. To calculate the interrelationships between the
atopic disorders, for every child’s EHR with sufﬁcient data quality and at
least 3 years of follow-up, it was determined whether he/she had one or
more atopic disorders or not, in the period from 2002–2014. All
calculations were conducted in Stata 13 and Excel 2010.
Ethical approval
Dutch law allows the use of anonymous EHR data for research purposes
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